CRIS Current Research Information System

LANDUZZI, LORENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.935
EU - Europa 2.724
AS - Asia 1.513
AF - Africa 192
SA - Sud America 7
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.377
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.894
IT - Italia 705
GB - Regno Unito 605
CN - Cina 599
DE - Germania 398
VN - Vietnam 369
SG - Singapore 339
SE - Svezia 284
CH - Svizzera 122
IN - India 114
UA - Ucraina 113
IE - Irlanda 104
RU - Federazione Russa 98
FR - Francia 92
CI - Costa d'Avorio 64
TG - Togo 57
ZA - Sudafrica 47
EE - Estonia 45
CA - Canada 41
BG - Bulgaria 38
FI - Finlandia 30
BE - Belgio 28
JO - Giordania 22
ID - Indonesia 21
NL - Olanda 20
JP - Giappone 17
RO - Romania 14
NG - Nigeria 11
SC - Seychelles 9
HK - Hong Kong 8
IR - Iran 7
AT - Austria 6
CL - Cile 5
GR - Grecia 5
DK - Danimarca 4
HR - Croazia 4
TR - Turchia 4
AU - Australia 3
EG - Egitto 3
KR - Corea 3
PK - Pakistan 3
PL - Polonia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
ES - Italia 2
LT - Lituania 2
MD - Moldavia 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BR - Brasile 1
IL - Israele 1
IQ - Iraq 1
LB - Libano 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
SN - Senegal 1
Totale 8.377
Salva come PNG Salva come JPEG
Città #
Southend 526
Fairfield 511
Chandler 481
Singapore 307
Ashburn 289
Ann Arbor 240
Woodbridge 237
Houston 217
Seattle 205
Wilmington 205
Dong Ket 198
Shanghai 173
Cambridge 166
Bologna 143
Santa Clara 141
Princeton 133
Bern 112
Dublin 104
Boardman 95
Jacksonville 75
Frankfurt am Main 69
Abidjan 64
Lomé 57
Westminster 53
Bremen 52
Nanjing 50
Padova 45
Berlin 41
Sofia 38
Beijing 36
Guangzhou 32
San Diego 31
Shenyang 29
Jinan 28
Milan 28
Brussels 27
Saint Petersburg 26
Des Moines 24
Helsinki 24
Turin 24
Ottawa 23
Redmond 23
Redwood City 23
Amman 22
Casalecchio di Reno 22
Jakarta 21
Hebei 19
Nanchang 19
Changsha 18
Mülheim 16
Amsterdam 14
Tianjin 14
Tokyo 14
Florence 12
Jiaxing 12
London 12
Verona 12
Phoenix 11
Abeokuta 10
Bühl 10
Falkenstein 10
Dearborn 9
Los Angeles 9
Mahé 9
Moscow 9
Parma 9
Zhengzhou 9
Catanzaro 8
Falls Church 8
Kuban 8
Toronto 8
Crocetta 7
Hong Kong 7
Kerpen 7
Leawood 7
Ningbo 7
Rome 7
Vicenza 7
Crotone 6
Haikou 6
Lanzhou 6
Naples 6
New York 6
Paris 6
Porto Recanati 6
Shijiazhuang 6
Taizhou 6
Vienna 6
Bulle 5
Dallas 5
Delhi 5
Lappeenranta 5
Reggio Nell'emilia 5
Shenzhen 5
Taiyuan 5
Chieti 4
Hangzhou 4
Montreal 4
Muizenberg 4
Olalla 4
Totale 5.923
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 314
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 249
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 225
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 210
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 176
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma 172
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 169
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. 161
CD99 Acts as an Oncosuppressor in Osteosarcoma. 157
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 155
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 151
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 150
Virus-like particle display of HER2 induces potent anti-cancer responses 150
Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). 148
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 147
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 146
An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. 143
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 137
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 137
Antimetastatic activity of a preventive cancer vaccine. 136
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 136
Immunoprevention and immunotherapy of mammary carcinoma 134
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. 133
Immunological prevention of a multigene cancer syndrome 132
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 130
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 129
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 128
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer 127
Targeting CD99 compromises the oncogenic effects of the chimera EWS-FLI1 by inducing re-expression of zyxin and inhibition of Gli1 activity 127
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. 126
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity 126
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 126
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 125
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. 124
In silico modeling and in vivo efficacy of cancer preventive vaccinations 124
Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma 122
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 121
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 120
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 119
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 119
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 117
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. 117
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 116
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 115
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 113
APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. 113
TRAF6 regulates proliferation and differentiation of skeletal myoblasts 112
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 111
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 111
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. 111
Molecular and cellular biology of rhabdomyosarcoma 109
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 109
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent 102
Vaccines and other immunological approaches for cancer immunoprevention 101
RIP2 regulates growth and differentiation of normal myoblasts and of rhabdomyosarcoma cells. 97
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 96
NVE-BEZ235 as a new therapeutic option for sarcomas. 95
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 93
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 83
Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. 83
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells 83
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma 74
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 69
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 64
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research 60
Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma. 59
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality 54
CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscape 36
Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma 34
IL-1 Family Members in Bone Sarcomas 30
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 19
Totale 8.647
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.752
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.752
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.274 0 0 0 0 0 179 243 279 260 136 87 90
2020/20211.244 190 62 35 64 26 48 43 132 130 57 49 408
2021/20221.471 122 48 104 58 123 86 39 107 81 128 337 238
2022/20231.923 183 227 111 277 123 132 67 104 278 73 176 172
2023/2024630 28 80 28 47 38 63 36 221 17 32 13 27
2024/20251.042 135 246 154 114 282 111 0 0 0 0 0 0
Totale 8.647